13078-13-2

Basic information

• Product Name: 1-(3-METHYLPHENYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE
• Synonyms: 1-(M-Tolyl)piperazine dihydrochloride hydrate;N-(m-Tolyl)piperazine Dihydrochloride;M-TOLYLPIPERAZINE HYDROCHLORIDE;N-(M-TOLYL)PIPERAZINE DIHYDROCHLORIDE;N-(M-TOLYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE;TIMTEC-BB SBB003158;1-(M-TOLYL)PIPERAZINE DI HCL;1-(M-TOLYL)PIPERAZINE DIHYDROCHLORIDE
• CAS NO: 13078-13-2
• Molecular Formula: C₁₁H₁₆N₂*2ClH
• Molecular Weight: 249.18
• EINECS: 235-974-8
• Mol File: 13078-13-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 195-202 °C
• Boiling Point: 321.4°Cat760mmHg
• Flash Point: 154°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.000299mmHg at 25°C
• CAS DataBase Reference: 1-(3-METHYLPHENYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-METHYLPHENYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE(13078-13-2)
• EPA Substance Registry System: 1-(3-METHYLPHENYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE(13078-13-2)

Safety Data

• Hazard Codes: T
• Statements: 36/37/38-24-22
• Safety Statements: 45-36/37/39-26
• Hazardous Substances Data: 13078-13-2(Hazardous Substances Data)

Usage

General Description

1-(3-Methylphenyl)piperazine dihydrochloride hydrate is a chemical compound that consists of a piperazine ring with a 3-methylphenyl group attached to it. It exists in a dihydrochloride salt form and is also found as a hydrate. 1-(3-METHYLPHENYL)PIPERAZINE DIHYDROCHLORIDE HYDRATE is commonly used in scientific research as a building block for the synthesis of various pharmaceuticals and organic compounds. It has potential applications in medicinal chemistry, particularly in the development of drugs targeting neurological disorders and psychiatric conditions. The dihydrochloride salt form enhances its stability and solubility, making it easier to handle and use in laboratory settings.

InChI:InChI=1/C11H16N2/c1-10-3-2-4-11(9-10)13-7-5-12-6-8-13/h2-4,9,12H,5-8H2,1H3/p+1

Upstream product

• 591-17-3 meta-bromotoluene 
• 1121596-67-5 tert-butyl 4-(m-tolyl)piperazine-1-carboxylate 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 108-44-1 1-amino-3-methylbenzene 

Downstream Products

• 126921-45-7 4-[2-(4-m-Tolyl-piperazin-1-yl)-ethyl]-quinoline 
• 95395-65-6 6-<2-<4-(3-methylphenyl)-1-piperazinyl>ethyl>-5,6,7,8-tetrahydro-1,6-naphthyridine difumarate 
• 898532-85-9 N-[4-[4-(m-tolyl)piperazin-1-yl]butyl]benzo[b]furan-2-carboxamide 
• 41186-03-2 1-(3-Methylphenyl)piperazine 
• 898533-09-0 (R)-(+)-N-[4-[4-(m-tolyl)piperazin-1-yl]butyl]-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxamide 
• 935654-15-2 (3-chlorophenyl)(4-(m-tolyl)piperazin-1-yl)methanone hydrochloride 
• 898533-48-7 1,6-bis(4-m-tolylpiperazin-1-yl)hexane 
• 1228436-20-1 1-(6-bromohexyl)-4-m-tolylpiperazine 
• 1159928-56-9 (1-methylpiperidin-4-yl)methyl 4-(3-methylphenyl)piperazine-1-carboxylate 
• 898533-05-6 (S)-(-)-N-(4-(4-m-tolylpiperazin-1-yl)butyl)-1-(benzyloxycarbonyl)-1,2,3,4-tetrahydroquinoline-2-carboxamide 
• 898533-00-1 N-[2-(1H-Indol-3-yl)ethyl]-3-(4-m-tolylpiperazin-1-yl)propanamide 
• 1166810-34-9 6-[4-(3-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine 
• 118856-49-8 N-[3-[4-(3-methylphenyl)-1-piperazinyl]propyloxy]phthalimide 
• 740806-43-3 1-(4-bromo-3-methyl-phenyl)-piperazine hydrochloride 

Relevant articles and documents

Discovery of small-molecule inhibitors of RUVBL1/2 ATPase

RUVBL1 and RUVBL2 are highly conserved AAA ATPases (ATPases Associated with various cellular Activities) and highly relevant to the progression of cancer, which makes them attractive targets for novel therapeutic anticancer drugs. In this work, docking-based virtual screening was performed to identify compounds with activity against the RUVBL1/2 complex. Seven compounds showed inhibitory activity against the complex in both enzymatic and cellular assays. A series of pyrazolo[1,5-a]pyrimidine-3-carboxamide analogs were synthesized based on the scaffold of compound 15 with inhibitory activity and good potential for structural manipulation. Analysis of the structure–activity relationship identified the benzyl group on R2 and aromatic ring-substituted piperazinyl on R4 as essential for inhibitory activity against the RUVBL1/2 complex. Of these, compound 18, which has IC50 values of 6.0 ± 0.6 μM and 7.7 ± 0.9 μM against RUVBL1/2 complex and RUVBL1 respectively, showed the most potent inhibition in cell lines A549, H1795, HCT116, and MDA-MB-231 with IC50 values of 15 ± 1.2 μM, 15 ± 1.8 μM, 11 ± 1.0 μM, and 8.9 ± 0.9 μM respectively. A docking study of the compound was performed to predict the binding mode of pyrazolo[1,5-a]pyrimidine-3-carboxamides. Furthermore, mass spectrometry-based proteomic analysis was employed to explore cellular proteins dysregulated by treatment with compounds 16, 18, and 19. Together, the data from these analyses suggest that that compound 18 could serve as a starting point for structural modifications in order to improve potency, selectivity, and pharmacokinetic parameters of potential therapeutic molecules.

Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles

A series of novel 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles possessing 1,2,4-triazole as the hydrogen-bond acceptor were designed, synthesized and evaluated for their antiproliferative and tubulin polymerization inhibitory activities. Some of them exhibited moderate activities in vitro against the three cancer cell lines including SGC-7901, A549 and HeLa. Compound 6e exhibited the highest potency against the three cancer cell lines. Moreover, the tubulin polymerization experiments indicated that compound 6e could inhibit the tubulin polymerization. Immunofluorescence study and cell cycle analysis clearly revealed compound 6e could disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. In addition, molecular docking analysis demonstrated the interaction of compound 6e at the colchicine-binding site of tubulin. These preliminary results suggested that compound 6e is a new colchicine binding site inhibitor and worthy of further investigation.

Discovery of aroyl piperazine derivatives as IKr & I Ks dual inhibitors for cardiac arrhythmia treatment

Combined blockade of IKr and IKs potassium channels is considered to be a promising therapeutic strategy for arrhythmia. In this study, we designed and synthesized 15 derivatives through modifying the hit compound 7 that was discovered by screening in-house database by whole-patch clamp technique. All of the compounds were evaluated on CHO and HEK 293 cell lines stably expressing hERG (IKr) and hKCNQ1/KCNE1 (IKs) potassium channels, and half of them exhibited improved dual IKr and IKs inhibitory effects compared to the hit compound. Compounds 7a and 7b with potent dual inhibitory activities were selected for further in vivo evaluations. Due to the preferable pharmacological behaviors, compound 7a deserved further optimization as a promising lead compound.